地中海内脏利什曼病的治疗
Treatment of Mediterranean visceral leishmaniasis.
作者信息
Gradoni L, Bryceson A, Desjeux P
机构信息
Laboratorio di Parassitologia, Istituto Superiore di Sanità, Rome, Italy.
出版信息
Bull World Health Organ. 1995;73(2):191-7.
Abstract
Up-to-date information is given on the epidemiological situation of zoonotic visceral leishmaniasis (ZVL) in nine Mediterranean countries, and on drug regimens adopted in the management of ZVL patients in each country. Results of experimental and clinical trials on the efficacy and tolerability of liposomal amphotericin B in laboratory animals and in patients with ZVL are presented, as well as conclusions and recommendations on drug regimens to be used in the treatment of ZVL.
摘要
提供了九个地中海国家人畜共患内脏利什曼病（ZVL）的流行病学最新情况，以及各国治疗ZVL患者所采用的药物治疗方案。介绍了脂质体两性霉素B在实验动物和ZVL患者中的疗效和耐受性的实验及临床试验结果，以及治疗ZVL所用药物治疗方案的结论和建议。
相似文献
1
Treatment of Mediterranean visceral leishmaniasis.地中海内脏利什曼病的治疗
Bull World Health Organ. 1995;73(2):191-7.
2
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?儿童内脏利什曼病的治疗：两性霉素B还是五价锑化合物？
Int J Antimicrob Agents. 2005 Jan;25(1):26-30. doi: 10.1016/j.ijantimicag.2004.09.011.
3
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.脂质体两性霉素B成功治疗感染人类免疫缺陷病毒患者的耐锑内脏利什曼病。
Clin Infect Dis. 1993 Oct;17(4):625-7. doi: 10.1093/clinids/17.4.625.
4
Drug regimens for visceral leishmaniasis in Mediterranean countries.地中海国家内脏利什曼病的药物治疗方案
Trop Med Int Health. 2008 Oct;13(10):1272-6. doi: 10.1111/j.1365-3156.2008.02144.x. Epub 2008 Aug 24.
5
[Treatment of visceral leishmaniasis in children].[儿童内脏利什曼病的治疗]
Med Trop (Mars). 2007 Feb;67(1):73-8.
6
[Visceral leishmaniasis: new drugs].[内脏利什曼病：新药]
Arch Pediatr. 2003 Dec;10 Suppl 5:550s-556s. doi: 10.1016/s0929-693x(03)90036-4.
7
Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.意大利西西里岛西部的儿童内脏利什曼病：111例回顾性分析
Eur J Clin Microbiol Infect Dis. 2002 Apr;21(4):277-82. doi: 10.1007/s10096-002-0707-3. Epub 2002 Apr 13.
8
Visceral leishmaniasis treatment, Italy.意大利的内脏利什曼病治疗
Emerg Infect Dis. 2003 Dec;9(12):1617-20. doi: 10.3201/eid0912.030178.
9
Pediatric visceral leishmaniasis in southern France.法国南部的儿童内脏利什曼病
Pediatr Infect Dis J. 1998 Aug;17(8):701-4. doi: 10.1097/00006454-199808000-00008.
10
[Treatment of infantile visceral leishmaniasis].[婴儿内脏利什曼病的治疗]
Arch Pediatr. 1999 Jan;6(1):59-66. doi: 10.1016/s0929-693x(99)80076-1.
引用本文的文献
1
Visceral Leishmaniasis (VL) Clinical Presentation, Laboratory Findings, Treatment Options and Outcome.内脏利什曼病（VL）的临床表现、实验室检查结果、治疗选择及预后
Iran J Parasitol. 2024 Jan-Mar;19(1):28-37. doi: 10.18502/ijpa.v19i1.15190.
2
Autochthonous and Imported Visceral Leishmaniasis in Bulgaria-Clinical Experience and Treatment of Patients.保加利亚本土及输入性内脏利什曼病——患者的临床经验与治疗
Pathogens. 2024 Feb 26;13(3):205. doi: 10.3390/pathogens13030205.
3
Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant With Increased Efficacy.短程治疗用鲨烯脂质体包封的丙咪嗪导致对锑耐药的实验内脏利什曼病无菌治愈，疗效增加。
Front Cell Infect Microbiol. 2020 Nov 10;10:595415. doi: 10.3389/fcimb.2020.595415. eCollection 2020.
4
Visceral leishmaniasis and HIV/AIDS in Brazil: Are we aware enough?巴西的内脏利什曼病与艾滋病毒/艾滋病：我们对此了解够多了吗？
PLoS Negl Trop Dis. 2017 Sep 25;11(9):e0005772. doi: 10.1371/journal.pntd.0005772. eCollection 2017 Sep.
5
Biodistribution and Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl--Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.1,2-二油酰基-琥珀酰基-β-甘油磷酰胆碱脂质体插层两性霉素 B 的体内分布和抗利什曼原虫活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.02525-16. Print 2017 Sep.
6
Comparative analyses of whole genome sequences of Leishmania infantum isolates from humans and dogs in northeastern Brazil.对巴西东北部人类和犬利什曼原虫分离株全基因组序列的比较分析。
Int J Parasitol. 2017 Sep;47(10-11):655-665. doi: 10.1016/j.ijpara.2017.04.004. Epub 2017 Jun 10.
7
Visceral Leishmaniasis as a Possible Reason for Pancytopenia.内脏利什曼病可能导致全血细胞减少症。
Front Pediatr. 2015 Jun 29;3:59. doi: 10.3389/fped.2015.00059. eCollection 2015.
8
Epidemiology of visceral leishmaniasis in Algeria: an update.阿尔及利亚内脏利什曼病的流行病学：最新情况
PLoS One. 2014 Jun 20;9(6):e99207. doi: 10.1371/journal.pone.0099207. eCollection 2014.
9
Therapeutic options for visceral leishmaniasis.内脏利什曼病的治疗选择。
Drugs. 2013 Nov;73(17):1863-88. doi: 10.1007/s40265-013-0133-0.
10
Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model.评价一种新型两性霉素 B 脂质体制剂在小鼠模型中的毒性和治疗效果。
Indian J Med Res. 2013 Apr;137(4):767-76.
本文引用的文献
1
Practical progress and new drugs for changing patterns of leishmaniasis.改变利什曼病模式的实际进展与新药
Parasitol Today. 1993 Sep;9(9):323-8. doi: 10.1016/0169-4758(93)90231-4.
2
The epidemiology and surveillance of visceral leishmaniasis in the Campania region of Italy. The value of zymodeme typing.意大利坎帕尼亚地区内脏利什曼病的流行病学与监测。酶谱分型的价值。
Epidemiol Infect. 1993 Oct;111(2):297-306. doi: 10.1017/s0950268800057009.
3
Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis.脂质体两性霉素B治疗意大利内脏利什曼病婴儿的疗效和耐受性
Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):477. doi: 10.1016/0035-9203(93)90045-r.
4
Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis.用脂质体两性霉素B治疗一名患有耐药性内脏利什曼病的儿童。
Trans R Soc Trop Med Hyg. 1993 May-Jun;87(3):310. doi: 10.1016/0035-9203(93)90141-c.
5
Liposomal amphotericin B in drug-resistant visceral leishmaniasis.脂质体两性霉素B治疗耐药性内脏利什曼病。
Lancet. 1991 May 4;337(8749):1061-2. doi: 10.1016/0140-6736(91)91708-3.
6
Prevalence of Leishmania infection among AIDS patients.艾滋病患者中利什曼原虫感染的患病率。
Lancet. 1992 Jun 6;339(8806):1427. doi: 10.1016/0140-6736(92)91255-7.
Zotero 插件